Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance

Andrew D. Spearman, Kevin Sweet, Xiao Ping Zhou, Jane McLennan, Fergus J Couch, Amanda Ewart Toland

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Purpose: Twenty percent of individuals with a strong family and/or personal history of breast and ovarian cancer carry a deleterious mutation in BRCA1 or BRCA2. Identification of mutations in these genes is extremely beneficial for patients pursuing risk reduction strategies. Approximately 7% of individuals who have genetic testing of BRCA1 and BRCA2 carry a variant of uncertain significance (VUS), making clinical management less certain. The majority of identified VUS occur only in one to two individuals; these variants are not able to be classified using current classification models with segregation analysis components. Methods: To develop a clinically applicable method that can predict the pathogenicity of VUS that does not require familial information or segregation analysis, we identified characteristics of breast or ovarian tumors that distinguished sporadic tumors from tumors with BRCA1 or BRCA2 mutations. Study participants included individuals with known deleterious mutations in BRCA1 or BRCA2 and individuals with classified or unclassified BRCA variants. Results: We applied the models to 57 tumors with 43 different deleterious BRCA mutations and 57 tumors with 54 unique classified and unclassified BRCA variants. Of the 33 previously unclassified VUS studied, we found evidence of neutrality for 21. Conclusion: Our models showed 98% sensitivity and 76% specificity for predicting classified DNA changes. We classified 64% of unknown variants as neutral. Classification of VUS as neutral will have immediate benefit for those individuals and their family members. These models are adaptable for the clinic and will be useful for individuals with limited available family history.

Original languageEnglish (US)
Pages (from-to)5393-5400
Number of pages8
JournalJournal of Clinical Oncology
Volume26
Issue number33
DOIs
StatePublished - Nov 20 2008

Fingerprint

Mutation
Neoplasms
Genetic Testing
Risk Reduction Behavior
Ovarian Neoplasms
Virulence
Breast
Breast Neoplasms
Sensitivity and Specificity
DNA
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. / Spearman, Andrew D.; Sweet, Kevin; Zhou, Xiao Ping; McLennan, Jane; Couch, Fergus J; Toland, Amanda Ewart.

In: Journal of Clinical Oncology, Vol. 26, No. 33, 20.11.2008, p. 5393-5400.

Research output: Contribution to journalArticle

Spearman, Andrew D. ; Sweet, Kevin ; Zhou, Xiao Ping ; McLennan, Jane ; Couch, Fergus J ; Toland, Amanda Ewart. / Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 33. pp. 5393-5400.
@article{b0205a66e01840da9ac6c5f4526b8793,
title = "Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance",
abstract = "Purpose: Twenty percent of individuals with a strong family and/or personal history of breast and ovarian cancer carry a deleterious mutation in BRCA1 or BRCA2. Identification of mutations in these genes is extremely beneficial for patients pursuing risk reduction strategies. Approximately 7{\%} of individuals who have genetic testing of BRCA1 and BRCA2 carry a variant of uncertain significance (VUS), making clinical management less certain. The majority of identified VUS occur only in one to two individuals; these variants are not able to be classified using current classification models with segregation analysis components. Methods: To develop a clinically applicable method that can predict the pathogenicity of VUS that does not require familial information or segregation analysis, we identified characteristics of breast or ovarian tumors that distinguished sporadic tumors from tumors with BRCA1 or BRCA2 mutations. Study participants included individuals with known deleterious mutations in BRCA1 or BRCA2 and individuals with classified or unclassified BRCA variants. Results: We applied the models to 57 tumors with 43 different deleterious BRCA mutations and 57 tumors with 54 unique classified and unclassified BRCA variants. Of the 33 previously unclassified VUS studied, we found evidence of neutrality for 21. Conclusion: Our models showed 98{\%} sensitivity and 76{\%} specificity for predicting classified DNA changes. We classified 64{\%} of unknown variants as neutral. Classification of VUS as neutral will have immediate benefit for those individuals and their family members. These models are adaptable for the clinic and will be useful for individuals with limited available family history.",
author = "Spearman, {Andrew D.} and Kevin Sweet and Zhou, {Xiao Ping} and Jane McLennan and Couch, {Fergus J} and Toland, {Amanda Ewart}",
year = "2008",
month = "11",
day = "20",
doi = "10.1200/JCO.2008.17.8228",
language = "English (US)",
volume = "26",
pages = "5393--5400",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "33",

}

TY - JOUR

T1 - Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance

AU - Spearman, Andrew D.

AU - Sweet, Kevin

AU - Zhou, Xiao Ping

AU - McLennan, Jane

AU - Couch, Fergus J

AU - Toland, Amanda Ewart

PY - 2008/11/20

Y1 - 2008/11/20

N2 - Purpose: Twenty percent of individuals with a strong family and/or personal history of breast and ovarian cancer carry a deleterious mutation in BRCA1 or BRCA2. Identification of mutations in these genes is extremely beneficial for patients pursuing risk reduction strategies. Approximately 7% of individuals who have genetic testing of BRCA1 and BRCA2 carry a variant of uncertain significance (VUS), making clinical management less certain. The majority of identified VUS occur only in one to two individuals; these variants are not able to be classified using current classification models with segregation analysis components. Methods: To develop a clinically applicable method that can predict the pathogenicity of VUS that does not require familial information or segregation analysis, we identified characteristics of breast or ovarian tumors that distinguished sporadic tumors from tumors with BRCA1 or BRCA2 mutations. Study participants included individuals with known deleterious mutations in BRCA1 or BRCA2 and individuals with classified or unclassified BRCA variants. Results: We applied the models to 57 tumors with 43 different deleterious BRCA mutations and 57 tumors with 54 unique classified and unclassified BRCA variants. Of the 33 previously unclassified VUS studied, we found evidence of neutrality for 21. Conclusion: Our models showed 98% sensitivity and 76% specificity for predicting classified DNA changes. We classified 64% of unknown variants as neutral. Classification of VUS as neutral will have immediate benefit for those individuals and their family members. These models are adaptable for the clinic and will be useful for individuals with limited available family history.

AB - Purpose: Twenty percent of individuals with a strong family and/or personal history of breast and ovarian cancer carry a deleterious mutation in BRCA1 or BRCA2. Identification of mutations in these genes is extremely beneficial for patients pursuing risk reduction strategies. Approximately 7% of individuals who have genetic testing of BRCA1 and BRCA2 carry a variant of uncertain significance (VUS), making clinical management less certain. The majority of identified VUS occur only in one to two individuals; these variants are not able to be classified using current classification models with segregation analysis components. Methods: To develop a clinically applicable method that can predict the pathogenicity of VUS that does not require familial information or segregation analysis, we identified characteristics of breast or ovarian tumors that distinguished sporadic tumors from tumors with BRCA1 or BRCA2 mutations. Study participants included individuals with known deleterious mutations in BRCA1 or BRCA2 and individuals with classified or unclassified BRCA variants. Results: We applied the models to 57 tumors with 43 different deleterious BRCA mutations and 57 tumors with 54 unique classified and unclassified BRCA variants. Of the 33 previously unclassified VUS studied, we found evidence of neutrality for 21. Conclusion: Our models showed 98% sensitivity and 76% specificity for predicting classified DNA changes. We classified 64% of unknown variants as neutral. Classification of VUS as neutral will have immediate benefit for those individuals and their family members. These models are adaptable for the clinic and will be useful for individuals with limited available family history.

UR - http://www.scopus.com/inward/record.url?scp=56749160290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749160290&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.17.8228

DO - 10.1200/JCO.2008.17.8228

M3 - Article

VL - 26

SP - 5393

EP - 5400

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 33

ER -